SPY345.66+3.65 1.07%
DIA284.70+2.67 0.95%
IXIC11,597.09+118.20 1.03%

The Cooper Companies' CooperVision Reports Six-Year Data From MiSight 1 Day Study Showed 23% of Eyes Showed No Additional Myopia Progression After Fitting

SAN RAMON, Calif., Oct. 9, 2020 /PRNewswire/ -- CooperVision is reporting the latest findings from its landmark MiSight® 1 day clinical study, providing new insights about myopia management and the proven efficacy of

· 10/09/2020 08:08

SAN RAMON, Calif., Oct. 9, 2020 /PRNewswire/ -- CooperVision is reporting the latest findings from its landmark MiSight® 1 day clinical study, providing new insights about myopia management and the proven efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children's eyes originally fit with MiSight® 1 day remain stable for myopia after six years.1

Paul Chamberlain, CooperVision's Director of Research Programs, will share additional details this evening, Friday, October 9 at 8:45 pm EST, during a paper presentation1 at the American Academy of Optometry's virtual annual meeting.

"Evaluating children who were prescribed MiSight® 1 day at the study's initiation, 23% of eyes after year six displayed a total refractive change of less than -0.25D (spherical equivalent), which could be considered clinically stable," said Chamberlain.1 "There is now even more reason to recognize the substantial capability of this unique dual-focus contact lens."

The newest findings also suggest that while intervention at an early age is optimal with MiSight® 1 day, commencing treatment at an older age could similarly slow the rate of myopia progression.1 The original control group was refit into the dual-focus lens in year four. Comparing this population to the children fit with MiSight® 1 day at initiation, there have been similar rates of myopia progression and axial length growth in the subsequent three years of assessment.1 

Six-year results continue to demonstrate excellent safety profile, wearing time, and visual acuity for children in daily disposable contact lenses over 653 wearing years.1 No other prospective randomized controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a soft contact lens over a similar time span.

Myopia—also known as nearsightedness or short-sightedness—is projected to affect the vision and increase risks to ocular health of approximately five billion people by 2050, more than doubling today's numbers.2 Myopic progression has been linked to sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma3 and myopic maculopathy.4